TNFRSF17 TNF receptor superfamily member 17
ENSG00000048462 · protein coding · Open Targets profile
Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. {ECO:0000269|PubMed:10801128, ECO:0000269|PubMed:10903733, ECO:0000269|PubMed:10973284}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- Approved Drug, GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
- PROTAC
- Database Ubiquitination
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 1.3068000078201294 (upper bound 2.077699899673462). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 151 registry trials, updated in the last three years, of the most advanced drugs against TNFRSF17 (idecabtagene vicleucel, ciltacabtagene autoleucel, elranatamab, teclistamab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Bristol-Myers SquibbBristol-Myers Squibb · 5 of 6 trials Phase 2+
- Alfred GarfallPenn Medicine · 2 of 2 trials Phase 2+
- Carl O LandgrenProfessor of Medicine · 2 of 2 trials Phase 2+
- Joan BladéHospital Clinic of Barcelona · 2 of 2 trials Phase 2+
- Niels van de DonkAmsterdam UMC, Vrije Universiteit Amsterdam · 2 of 2 trials Phase 2+
- Noopur RajeMassachusetts General Hospital · 2 of 2 trials Phase 2+
- Kailin XuThe Affiliated Hospital oh Xuzhou Medical University · 1 of 2 trials Phase 2+
- Michael SladeWashington University School of Medicine · 1 of 2 trials Phase 2+
- Murali JanakiramCity of Hope Medical Center · 1 of 2 trials Phase 2+
- Ah-Reum JeongUniversity of California, San Diego · 1 of 1 trials Phase 2+
- Albert OriolInstitut Català d'Oncologia - Hospital Germans Trias i Pujol · 1 of 1 trials Phase 2+
- Alessandra LaroccaA.O.U. Città della Salute e della Scienza di Torino · 1 of 1 trials Phase 2+
- Alexander LesokhinMemorial Sloan Kettering Cancer Center · 1 of 1 trials Phase 2+
- Andrew BranaganMassachusetts General Hospital · 1 of 1 trials Phase 2+
- Andrew YeeMassachusetts General Hospital · 1 of 1 trials Phase 2+
Registry trials of idecabtagene vicleucel, ciltacabtagene autoleucel, elranatamab, teclistamab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 87 of 139 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 12 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
8 trials of drugs against TNFRSF17 were stopped early
Terminated, withdrawn and suspended interventional trials of idecabtagene vicleucel, ciltacabtagene autoleucel, elranatamab, teclistamab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 8 most recent of 8.
- suspended · 2026-10-19 · National Cancer Institute (NCI) · matched by the registry's drug synonyms“Scheduled Interim Monitoring”
- terminated · 2026-07-09 · Celgene · matched by the registry's drug synonyms“Business objectives have changed”
- terminated · 2026-04-24 · Pfizer · Elranatamab + Nirogacestat, Elranatamab + lenalidomide + dexamethasone“A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.”
- terminated · 2025-12-17 · Nanjing Legend Biotech Co. · matched by the registry's drug synonyms“The study was terminated early due to a strategic realignment of the sponsor's business plan, not related to safety, efficacy, or data integrity concerns.”
- terminated · 2025-07-29 · University of Washington · Teclistamab“Study terminated due to end of funding.”
- withdrawn · 2025-03-03 · Jack Khouri, MD · Teclistamab(FDA-approved)“Funding unavailable”
- terminated · 2023-10-19 · Kite, A Gilead Company · matched by the registry's drug synonyms“The study was terminated due to lack of efficacy”
- terminated · 2023-09-21 · Precision BioSciences, Inc. · matched by the registry's drug synonyms“Study was terminated due to lack of sufficient therapeutic effect”
Paediatric incentives and obligations for TNFRSF17's drugs
For idecabtagene vicleucel, ciltacabtagene autoleucel, elranatamab, teclistamab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · TNFRSF17 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-002369-PIP01-18-M02 (idecabtagene vicleucel, Treatment of mature B-cell neoplasms): W: decision granting a waiver in all age groups for all conditions or indications, 19 Feb 2021Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-002369-PIP01-18-M02, 2026-11-11
- EU orphan designation: yes · EU/3/20/2331 withdrawn 19 Jul 2022: Treatment of multiple myeloma; EU/3/20/2252 positive 28 Feb 2020: Treatment of multiple myeloma; EU/3/17/1863 positive 20 Apr 2017: Treatment of multiple myelomaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Tecvayli: authorised since 23 Aug 2022; Carvykti: authorised since 25 May 2022, orphan medicine; Elrexfio: authorised since 7 Dec 2023, conditional; Abecma: authorised since 18 Aug 2021, orphan medicineRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of idecabtagene vicleucel, ciltacabtagene autoleucel, elranatamab, teclistamabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 2 interventional studies of idecabtagene vicleucel, ciltacabtagene autoleucel, elranatamab, teclistamab include patients under 18; 2 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 5 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.